Search

Your search keyword '"Roxanis, Ioannis"' showing total 240 results
Start Over Author "Roxanis, Ioannis"
240 results on '"Roxanis, Ioannis"'

1. SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response

Author

Bland, Philip, Saville, Harry, Wai, Patty T., Curnow, Lucinda, Muirhead, Gareth, Nieminuszczy, Jadwiga, Ravindran, Nivedita, John, Marie Beatrix, Hedayat, Somaieh, Barker, Holly E., Wright, James, Yu, Lu, Mavrommati, Ioanna, Read, Abigail, Peck, Barrie, Allen, Mark, Gazinska, Patrycja, Pemberton, Helen N., Gulati, Aditi, Nash, Sarah, Noor, Farzana, Guppy, Naomi, Roxanis, Ioannis, Pratt, Guy, Oldreive, Ceri, Stankovic, Tatjana, Barlow, Samantha, Kalirai, Helen, Coupland, Sarah E., Broderick, Ronan, Alsafadi, Samar, Houy, Alexandre, Stern, Marc-Henri, Pettit, Stephen, Choudhary, Jyoti S., Haider, Syed, Niedzwiedz, Wojciech, Lord, Christopher J., and Natrajan, Rachael

Published
2023
Full Text
View/download PDF

4. Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation

Author

Dillon, Magnus T., Guevara, Jeane, Mohammed, Kabir, Patin, Emmanuel C., Smith, Simon A., Dean, Emma, Jones, Gemma N., Willis, Sophie E., Petrone, Marcella, Silva, Carlos, Thway, Khin, Bunce, Catey, Roxanis, Ioannis, Nenclares, Pablo, Wilkins, Anna, McLaughlin, Martin, Jayme-Laiche, Adoracion, Benafif, Sarah, Nintos, Georgios, Kwatra, Vineet, Grove, Lorna, Mansfield, David, Proszek, Paula, Martin, Philip, Moore, Luiza, Swales, Karen E., Banerji, Udai, Saunders, Mark P., Spicer, James, Forster, Martin D., and Harrington, Kevin J.

Subjects
Tumors -- Drug therapy -- Genetic aspects, Inflammation -- Drug therapy -- Genetic aspects, Health care industry
Abstract

BACKGROUND. Phase 1 study of ATR inhibition alone or with radiation therapy (PATRIOT) was a first-in-human phase I study of the oral ATR (ataxia telangiectasia and Rad3-related) inhibitor ceralasertib (AZD6738) in advanced solid tumors. METHODS. The primary objective was safety. Secondary objectives included assessment of antitumor responses and pharmacokinetic (PK) and pharmacodynamic (PD) studies. Sixty-seven patients received 20-240 mg ceralasertib BD continuously or intermittently (14 of a 28-day cycle). RESULTS. Intermittent dosing was better tolerated than continuous, which was associated with dose-limiting hematological toxicity. The recommended phase 2 dose of ceralasertib was 160 mg twice daily for 2 weeks in a 4-weekly cycle. Modulation of target and increased DNA damage were identified in tumor and surrogate PD. There were 5 (8%) confirmed partial responses (PRs) (40-240 mg BD), 34 (52%) stable disease (SD), including 1 unconfirmed PR, and 27 (41%) progressive disease. Durable responses were seen in tumors with loss of AT-rich interactive domain-containing protein 1A (ARID1A) and DNA damageresponse defects. Treatment-modulated tumor and systemic immune markers and responding tumors were more immune inflamed than nonresponding. CONCLUSION. Ceralasertib monotherapy was tolerated at 160 mg BD intermittently and associated with antitumor activity. TRIAL REGISTRATION. Clinicaltrials.gov: NCT02223923, EudraCT: 2013-003994-84. FUNDING. Cancer Research UK, AstraZeneca, UK Department of Health (National Institute for Health Research), Rosetrees Trust, Experimental Cancer Medicine Centre., Introduction ATR (ataxia telangiectasia and Rad3-related) is a critical kinase in the DNA damage response (DDR) (1, 2). Preclinical data have identified multiple cancer-related phenotypes sensitizing tumor cells to monotherapy [...]

Published
2024
Full Text
View/download PDF

5. Capturing global spatial context for accurate cell classification in skin cancer histology

Author

Zormpas-Petridis, Konstantinos, Failmezger, Henrik, Roxanis, Ioannis, Blackledge, Matthew, Jamin, Yann, and Yuan, Yinyin

Subjects
Computer Science - Computer Vision and Pattern Recognition
Abstract

The spectacular response observed in clinical trials of immunotherapy in patients with previously uncurable Melanoma, a highly aggressive form of skin cancer, calls for a better understanding of the cancer-immune interface. Computational pathology provides a unique opportunity to spatially dissect such interface on digitised pathological slides. Accurate cellular classification is a key to ensure meaningful results, but is often challenging even with state-of-art machine learning and deep learning methods. We propose a hierarchical framework, which mirrors the way pathologists perceive tumour architecture and define tumour heterogeneity to improve cell classification methods that rely solely on cell nuclei morphology. The SLIC superpixel algorithm was used to segment and classify tumour regions in low resolution H&E-stained histological images of melanoma skin cancer to provide a global context. Classification of superpixels into tumour, stroma, epidermis and lumen/white space, yielded a 97.7% training set accuracy and 95.7% testing set accuracy in 58 whole-tumour images of the TCGA melanoma dataset. The superpixel classification was projected down to high resolution images to enhance the performance of a single cell classifier, based on cell nuclear morphological features, and resulted in increasing its accuracy from 86.4% to 91.6%. Furthermore, a voting scheme was proposed to use global context as biological a priori knowledge, pushing the accuracy further to 92.8%. This study demonstrates how using the global spatial context can accurately characterise the tumour microenvironment and allow us to extend significantly beyond single-cell morphological classification., Comment: Accepted by MICCAI COMPAY 2018 workshop

Published
2018

7. Anti-EGFR antibody-drug conjugate carrying an inhibitor targeting CDK restricts triple-negative breast cancer growth

Author

Cheung, Anthony, primary, Chenoweth, Alicia M., additional, Johansson, Annelie, additional, Laddach, Roman, additional, Guppy, Naomi, additional, Trendell, Jennifer, additional, Esapa, Benjamina, additional, Mavousian, Antranik, additional, Navarro-Llinas, Blanca, additional, Haider, Syed, additional, Romero-Clavijo, Pablo, additional, Hoffmann, Ricarda M., additional, Andriollo, Paolo, additional, Rahman, Khondaker Miraz, additional, Jackson, Paul, additional, Tsoka, Sophia, additional, Irshad, Sheeba, additional, Roxanis, Ioannis, additional, Grigoriadis, Anita, additional, Thurston, David E., additional, Lord, Christopher J., additional, Tutt, Andrew N.J., additional, and Karagiannis, Sophia N., additional

Published
2024
Full Text
View/download PDF

8. A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death

Author

Mannion, Jonathan, primary, Gifford, Valentina, additional, Bellenie, Benjamin, additional, Fernando, Winnie, additional, Ramos Garcia, Laura, additional, Wilson, Rebecca, additional, John, Sidonie Wicky, additional, Udainiya, Savita, additional, Patin, Emmanuel C., additional, Tiu, Crescens, additional, Smith, Angel, additional, Goicoechea, Maria, additional, Craxton, Andrew, additional, Moraes de Vasconcelos, Nathalia, additional, Guppy, Naomi, additional, Cheung, Kwai-Ming J., additional, Cundy, Nicholas J., additional, Pierrat, Olivier, additional, Brennan, Alfie, additional, Roumeliotis, Theodoros I., additional, Benstead-Hume, Graeme, additional, Alexander, John, additional, Muirhead, Gareth, additional, Layzell, Scott, additional, Lyu, Wenxin, additional, Roulstone, Victoria, additional, Allen, Mark, additional, Baldock, Holly, additional, Legrand, Arnaud, additional, Gabel, Florian, additional, Serrano-Aparicio, Natalia, additional, Starling, Chris, additional, Guo, Hongyan, additional, Upton, Jason, additional, Gyrd-Hansen, Mads, additional, MacFarlane, Marion, additional, Seddon, Benedict, additional, Raynaud, Florence, additional, Roxanis, Ioannis, additional, Harrington, Kevin, additional, Haider, Syed, additional, Choudhary, Jyoti S., additional, Hoelder, Swen, additional, Tenev, Tencho, additional, and Meier, Pascal, additional

Published
2024
Full Text
View/download PDF

10. Longitudinal assessment of tumor-infiltrating lymphocytes in primary breast cancer following neoadjuvant radiotherapy

Author

Yoneyama, Miki, primary, Zormpas-Petridis, Konstantinos, additional, Robinson, Ruth, additional, Sobhani, Faranak, additional, Provenzano, Elena, additional, Steel, Harriet, additional, Lightowlers, Sara, additional, Towns, Catherine, additional, Castillo, Simon P., additional, Anbalagan, Selvakumar, additional, Lund, Tom, additional, Wennerberg, Erik, additional, Melcher, Alan, additional, Coles, Charlotte E., additional, Roxanis, Ioannis, additional, Yuan, Yinyin, additional, and Somaiah, Navita, additional

Published
2024
Full Text
View/download PDF

12. Ubiquitylation of MLKL at lysine 219 positively regulates necroptosis-induced tissue injury and pathogen clearance

Author

Garcia, Laura Ramos, Tenev, Tencho, Newman, Richard, Haich, Rachel O., Liccardi, Gianmaria, John, Sidonie Wicky, Annibaldi, Alessandro, Yu, Lu, Pardo, Mercedes, Young, Samuel N., Fitzgibbon, Cheree, Fernando, Winnie, Guppy, Naomi, Kim, Hyojin, Liang, Lung-Yu, Lucet, Isabelle S., Kueh, Andrew, Roxanis, Ioannis, Gazinska, Patrycja, Sims, Martin, Smyth, Tomoko, Ward, George, Bertin, John, Beal, Allison M., Geddes, Brad, Choudhary, Jyoti S., Murphy, James M., Aurelia Ball, K., Upton, Jason W., and Meier, Pascal

Published
2021
Full Text
View/download PDF

14. Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer

Author

Lord, Simon R., Cheng, Wei-Chen, Liu, Dan, Gaude, Edoardo, Haider, Syed, Metcalf, Tom, Patel, Neel, Teoh, Eugene J., Gleeson, Fergus, Bradley, Kevin, Wigfield, Simon, Zois, Christos, McGowan, Daniel R., Ah-See, Mei-Lin, Thompson, Alastair M., Sharma, Anand, Bidaut, Luc, Pollak, Michael, Roy, Pankaj G., Karpe, Fredrik, James, Tim, English, Ruth, Adams, Rosie F., Campo, Leticia, Ayers, Lisa, Snell, Cameron, Roxanis, Ioannis, Frezza, Christian, Fenwick, John D., Buffa, Francesca M., and Harris, Adrian L.

Published
2018
Full Text
View/download PDF

15. Clinical whole-genome sequencing from routine formalin-fixed, paraffin-embedded specimens: pilot study for the 100,000 Genomes Project

Author

Robbe, Pauline, Popitsch, Niko, Knight, Samantha J.L., Antoniou, Pavlos, Becq, Jennifer, He, Miao, Kanapin, Alexander, Samsonova, Anastasia, Vavoulis, Dimitrios V., Ross, Mark T., Kingsbury, Zoya, Cabes, Maite, Ramos, Sara D.C., Page, Suzanne, Dreau, Helene, Ridout, Kate, Jones, Louise J., Tuff-Lacey, Alice, Henderson, Shirley, Mason, Joanne, Buffa, Francesca M., Verrill, Clare, Maldonado-Perez, David, Roxanis, Ioannis, Collantes, Elena, Browning, Lisa, Dhar, Sunanda, Damato, Stephen, Davies, Susan, Caulfield, Mark, Bentley, David R., Taylor, Jenny C., Turnbull, Clare, and Schuh, Anna

Published
2018
Full Text
View/download PDF

16. 1013: Imaging and transcriptomic biomarkers of breast tumour response to radiotherapy in the KORTUC trial

Author

Durie, Emily, Morris, Megan, Anbalagan, Selvakumar, Chauhan, Ritika, Price, Daniel, Roxanis, Ioannis, Tunariu, Nina, Sinnett, Victoria, Salehi-Bird, Seema, Healy, Nuala, Seth, Archana, Allen, Steven, Gothard, Lone, Hughes, Justine, Harrington, Kevin, Ladame, Sylvain, Mansfeld, Joerg, Tang, Meng-Xing, Blackledge, Matthew, and Somaiah, Navita

Published
2024
Full Text
View/download PDF

17. Figure 4 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

Author

Tovey, Holly, primary, Sipos, Orsolya, primary, Parker, Joel S., primary, Hoadley, Katherine A., primary, Quist, Jelmar, primary, Kernaghan, Sarah, primary, Kilburn, Lucy, primary, Salgado, Roberto, primary, Loi, Sherene, primary, Kennedy, Richard D., primary, Roxanis, Ioannis, primary, Gazinska, Patrycja, primary, Pinder, Sarah E., primary, Bliss, Judith, primary, Perou, Charles M., primary, Haider, Syed, primary, Grigoriadis, Anita, primary, Tutt, Andrew, primary, and Cheang, Maggie Chon U., primary

Published
2023
Full Text
View/download PDF

18. Figure 2 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

Author

Tovey, Holly, primary, Sipos, Orsolya, primary, Parker, Joel S., primary, Hoadley, Katherine A., primary, Quist, Jelmar, primary, Kernaghan, Sarah, primary, Kilburn, Lucy, primary, Salgado, Roberto, primary, Loi, Sherene, primary, Kennedy, Richard D., primary, Roxanis, Ioannis, primary, Gazinska, Patrycja, primary, Pinder, Sarah E., primary, Bliss, Judith, primary, Perou, Charles M., primary, Haider, Syed, primary, Grigoriadis, Anita, primary, Tutt, Andrew, primary, and Cheang, Maggie Chon U., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure S1 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

Author

Tovey, Holly, primary, Sipos, Orsolya, primary, Parker, Joel S., primary, Hoadley, Katherine A., primary, Quist, Jelmar, primary, Kernaghan, Sarah, primary, Kilburn, Lucy, primary, Salgado, Roberto, primary, Loi, Sherene, primary, Kennedy, Richard D., primary, Roxanis, Ioannis, primary, Gazinska, Patrycja, primary, Pinder, Sarah E., primary, Bliss, Judith, primary, Perou, Charles M., primary, Haider, Syed, primary, Grigoriadis, Anita, primary, Tutt, Andrew, primary, and Cheang, Maggie Chon U., primary

Published
2023
Full Text
View/download PDF

20. Table 1 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

Author

Tovey, Holly, primary, Sipos, Orsolya, primary, Parker, Joel S., primary, Hoadley, Katherine A., primary, Quist, Jelmar, primary, Kernaghan, Sarah, primary, Kilburn, Lucy, primary, Salgado, Roberto, primary, Loi, Sherene, primary, Kennedy, Richard D., primary, Roxanis, Ioannis, primary, Gazinska, Patrycja, primary, Pinder, Sarah E., primary, Bliss, Judith, primary, Perou, Charles M., primary, Haider, Syed, primary, Grigoriadis, Anita, primary, Tutt, Andrew, primary, and Cheang, Maggie Chon U., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Table S3 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

Author

Tovey, Holly, primary, Sipos, Orsolya, primary, Parker, Joel S., primary, Hoadley, Katherine A., primary, Quist, Jelmar, primary, Kernaghan, Sarah, primary, Kilburn, Lucy, primary, Salgado, Roberto, primary, Loi, Sherene, primary, Kennedy, Richard D., primary, Roxanis, Ioannis, primary, Gazinska, Patrycja, primary, Pinder, Sarah E., primary, Bliss, Judith, primary, Perou, Charles M., primary, Haider, Syed, primary, Grigoriadis, Anita, primary, Tutt, Andrew, primary, and Cheang, Maggie Chon U., primary

Published
2023
Full Text
View/download PDF

22. Data from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

Author

Tovey, Holly, primary, Sipos, Orsolya, primary, Parker, Joel S., primary, Hoadley, Katherine A., primary, Quist, Jelmar, primary, Kernaghan, Sarah, primary, Kilburn, Lucy, primary, Salgado, Roberto, primary, Loi, Sherene, primary, Kennedy, Richard D., primary, Roxanis, Ioannis, primary, Gazinska, Patrycja, primary, Pinder, Sarah E., primary, Bliss, Judith, primary, Perou, Charles M., primary, Haider, Syed, primary, Grigoriadis, Anita, primary, Tutt, Andrew, primary, and Cheang, Maggie Chon U., primary

Published
2023
Full Text
View/download PDF

23. Figure 3 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

Author

Tovey, Holly, primary, Sipos, Orsolya, primary, Parker, Joel S., primary, Hoadley, Katherine A., primary, Quist, Jelmar, primary, Kernaghan, Sarah, primary, Kilburn, Lucy, primary, Salgado, Roberto, primary, Loi, Sherene, primary, Kennedy, Richard D., primary, Roxanis, Ioannis, primary, Gazinska, Patrycja, primary, Pinder, Sarah E., primary, Bliss, Judith, primary, Perou, Charles M., primary, Haider, Syed, primary, Grigoriadis, Anita, primary, Tutt, Andrew, primary, and Cheang, Maggie Chon U., primary

Published
2023
Full Text
View/download PDF

24. Figure 5 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

Author

Tovey, Holly, primary, Sipos, Orsolya, primary, Parker, Joel S., primary, Hoadley, Katherine A., primary, Quist, Jelmar, primary, Kernaghan, Sarah, primary, Kilburn, Lucy, primary, Salgado, Roberto, primary, Loi, Sherene, primary, Kennedy, Richard D., primary, Roxanis, Ioannis, primary, Gazinska, Patrycja, primary, Pinder, Sarah E., primary, Bliss, Judith, primary, Perou, Charles M., primary, Haider, Syed, primary, Grigoriadis, Anita, primary, Tutt, Andrew, primary, and Cheang, Maggie Chon U., primary

Published
2023
Full Text
View/download PDF

25. Figure 1 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

Author

Tovey, Holly, primary, Sipos, Orsolya, primary, Parker, Joel S., primary, Hoadley, Katherine A., primary, Quist, Jelmar, primary, Kernaghan, Sarah, primary, Kilburn, Lucy, primary, Salgado, Roberto, primary, Loi, Sherene, primary, Kennedy, Richard D., primary, Roxanis, Ioannis, primary, Gazinska, Patrycja, primary, Pinder, Sarah E., primary, Bliss, Judith, primary, Perou, Charles M., primary, Haider, Syed, primary, Grigoriadis, Anita, primary, Tutt, Andrew, primary, and Cheang, Maggie Chon U., primary

Published
2023
Full Text
View/download PDF

26. Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

Author

Tovey, Holly, primary, Sipos, Orsolya, additional, Parker, Joel S., additional, Hoadley, Katherine A., additional, Quist, Jelmar, additional, Kernaghan, Sarah, additional, Kilburn, Lucy, additional, Salgado, Roberto, additional, Loi, Sherene, additional, Kennedy, Richard D., additional, Roxanis, Ioannis, additional, Gazinska, Patrycja, additional, Pinder, Sarah E., additional, Bliss, Judith, additional, Perou, Charles M., additional, Haider, Syed, additional, Grigoriadis, Anita, additional, Tutt, Andrew, additional, and Cheang, Maggie Chon U., additional

Published
2023
Full Text
View/download PDF

28. Serum-derived extracellular vesicles from breast cancer patients contribute to differential regulation of T-cell-mediated immune-escape mechanisms in breast cancer subtypes

Author

Graham, Rosalind, primary, Gazinska, Patrycja, additional, Zhang, Birong, additional, Khiabany, Atousa, additional, Sinha, Shubhankar, additional, Alaguthurai, Thanussuyah, additional, Flores-Borja, Fabian, additional, Vicencio, Jose, additional, Beuron, Fabienne, additional, Roxanis, Ioannis, additional, Matkowski, Rafal, additional, Liam-Or, Revadee, additional, Tutt, Andrew, additional, Ng, Tony, additional, Al-Jamal, Khuloud T., additional, Zhou, You, additional, and Irshad, Sheeba, additional

Published
2023
Full Text
View/download PDF

30. Abstract 6094: Longitudinal analysis of PARP inhibitor and platinum resistance in BRCA1/2m breast cancer using liquid biopsy

Author

Harvey-Jones, Elizabeth, primary, Raghunandan, Maya, additional, Robbez-Masson, Luisa, additional, Thanussuyah, Alaguthurai, additional, Liccardo, Roberta, additional, Yablonovitch, Arielle, additional, Cai, Mingyang, additional, Drusbosky, Leylah, additional, Dorschner, Michael, additional, Pardo, Lorena Magraner, additional, Marlow, Rebecca, additional, Konde, Asha, additional, Trendell, Jennifer, additional, Alexander, John, additional, Haider, Syed, additional, Starling, Chris, additional, Roxanis, Ioannis, additional, Yen, Jennifer, additional, Pettitt, Stephen J., additional, Lord, Christopher J., additional, and Tutt, Andrew N., additional

Published
2023
Full Text
View/download PDF

31. Supplementary Figure 3 from ADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression

Author

Sheldon, Helen, primary, Bridges, Esther, primary, Silva, Ildefonso, primary, Masiero, Massimo, primary, Favara, David M., primary, Wang, Dian, primary, Leek, Russell, primary, Snell, Cameron, primary, Roxanis, Ioannis, primary, Kreuzer, Mira, primary, Gileadi, Uzi, primary, Buffa, Francesca M., primary, Banham, Alison, primary, and Harris, Adrian L., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure 2 from ADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression

Author

Sheldon, Helen, primary, Bridges, Esther, primary, Silva, Ildefonso, primary, Masiero, Massimo, primary, Favara, David M., primary, Wang, Dian, primary, Leek, Russell, primary, Snell, Cameron, primary, Roxanis, Ioannis, primary, Kreuzer, Mira, primary, Gileadi, Uzi, primary, Buffa, Francesca M., primary, Banham, Alison, primary, and Harris, Adrian L., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure 5 from ADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression

Author

Sheldon, Helen, primary, Bridges, Esther, primary, Silva, Ildefonso, primary, Masiero, Massimo, primary, Favara, David M., primary, Wang, Dian, primary, Leek, Russell, primary, Snell, Cameron, primary, Roxanis, Ioannis, primary, Kreuzer, Mira, primary, Gileadi, Uzi, primary, Buffa, Francesca M., primary, Banham, Alison, primary, and Harris, Adrian L., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figure 7 from ADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression

Author

Sheldon, Helen, primary, Bridges, Esther, primary, Silva, Ildefonso, primary, Masiero, Massimo, primary, Favara, David M., primary, Wang, Dian, primary, Leek, Russell, primary, Snell, Cameron, primary, Roxanis, Ioannis, primary, Kreuzer, Mira, primary, Gileadi, Uzi, primary, Buffa, Francesca M., primary, Banham, Alison, primary, and Harris, Adrian L., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure 8 from ADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression

Author

Sheldon, Helen, primary, Bridges, Esther, primary, Silva, Ildefonso, primary, Masiero, Massimo, primary, Favara, David M., primary, Wang, Dian, primary, Leek, Russell, primary, Snell, Cameron, primary, Roxanis, Ioannis, primary, Kreuzer, Mira, primary, Gileadi, Uzi, primary, Buffa, Francesca M., primary, Banham, Alison, primary, and Harris, Adrian L., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure 6 from ADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression

Author

Sheldon, Helen, primary, Bridges, Esther, primary, Silva, Ildefonso, primary, Masiero, Massimo, primary, Favara, David M., primary, Wang, Dian, primary, Leek, Russell, primary, Snell, Cameron, primary, Roxanis, Ioannis, primary, Kreuzer, Mira, primary, Gileadi, Uzi, primary, Buffa, Francesca M., primary, Banham, Alison, primary, and Harris, Adrian L., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure 1 from ADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression

Author

Sheldon, Helen, primary, Bridges, Esther, primary, Silva, Ildefonso, primary, Masiero, Massimo, primary, Favara, David M., primary, Wang, Dian, primary, Leek, Russell, primary, Snell, Cameron, primary, Roxanis, Ioannis, primary, Kreuzer, Mira, primary, Gileadi, Uzi, primary, Buffa, Francesca M., primary, Banham, Alison, primary, and Harris, Adrian L., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure 4 from ADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression

Author

Sheldon, Helen, primary, Bridges, Esther, primary, Silva, Ildefonso, primary, Masiero, Massimo, primary, Favara, David M., primary, Wang, Dian, primary, Leek, Russell, primary, Snell, Cameron, primary, Roxanis, Ioannis, primary, Kreuzer, Mira, primary, Gileadi, Uzi, primary, Buffa, Francesca M., primary, Banham, Alison, primary, and Harris, Adrian L., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure and Table Legends from ADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression

Author

Sheldon, Helen, primary, Bridges, Esther, primary, Silva, Ildefonso, primary, Masiero, Massimo, primary, Favara, David M., primary, Wang, Dian, primary, Leek, Russell, primary, Snell, Cameron, primary, Roxanis, Ioannis, primary, Kreuzer, Mira, primary, Gileadi, Uzi, primary, Buffa, Francesca M., primary, Banham, Alison, primary, and Harris, Adrian L., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Table 2 from ADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression

Author

Sheldon, Helen, primary, Bridges, Esther, primary, Silva, Ildefonso, primary, Masiero, Massimo, primary, Favara, David M., primary, Wang, Dian, primary, Leek, Russell, primary, Snell, Cameron, primary, Roxanis, Ioannis, primary, Kreuzer, Mira, primary, Gileadi, Uzi, primary, Buffa, Francesca M., primary, Banham, Alison, primary, and Harris, Adrian L., primary

Published
2023
Full Text
View/download PDF

41. Data from ADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression

Author

Sheldon, Helen, primary, Bridges, Esther, primary, Silva, Ildefonso, primary, Masiero, Massimo, primary, Favara, David M., primary, Wang, Dian, primary, Leek, Russell, primary, Snell, Cameron, primary, Roxanis, Ioannis, primary, Kreuzer, Mira, primary, Gileadi, Uzi, primary, Buffa, Francesca M., primary, Banham, Alison, primary, and Harris, Adrian L., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Table 1 from ADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression

Author

Sheldon, Helen, primary, Bridges, Esther, primary, Silva, Ildefonso, primary, Masiero, Massimo, primary, Favara, David M., primary, Wang, Dian, primary, Leek, Russell, primary, Snell, Cameron, primary, Roxanis, Ioannis, primary, Kreuzer, Mira, primary, Gileadi, Uzi, primary, Buffa, Francesca M., primary, Banham, Alison, primary, and Harris, Adrian L., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Data from Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy–Resistant Early Breast Cancers

Author

Gazinska, Patrycja, primary, Milton, Charlotte, primary, Iacovacci, Jacopo, primary, Ward, Joseph, primary, Buus, Richard, primary, Alaguthurai, Thanussuyah, primary, Graham, Rosalind, primary, Akarca, Ayse, primary, Lips, Esther, primary, Naidoo, Kalnisha, primary, Wesseling, Jelle, primary, Marafioti, Teresa, primary, Cheang, Maggie, primary, Gillett, Cheryl, primary, Wu, Yin, primary, Khan, Aadil, primary, Melcher, Alan, primary, Salgado, Roberto, primary, Dowsett, Mitch, primary, Tutt, Andrew, primary, Roxanis, Ioannis, primary, Haider, Syed, primary, and Irshad, Sheeba, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figure from Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy–Resistant Early Breast Cancers

Author

Gazinska, Patrycja, primary, Milton, Charlotte, primary, Iacovacci, Jacopo, primary, Ward, Joseph, primary, Buus, Richard, primary, Alaguthurai, Thanussuyah, primary, Graham, Rosalind, primary, Akarca, Ayse, primary, Lips, Esther, primary, Naidoo, Kalnisha, primary, Wesseling, Jelle, primary, Marafioti, Teresa, primary, Cheang, Maggie, primary, Gillett, Cheryl, primary, Wu, Yin, primary, Khan, Aadil, primary, Melcher, Alan, primary, Salgado, Roberto, primary, Dowsett, Mitch, primary, Tutt, Andrew, primary, Roxanis, Ioannis, primary, Haider, Syed, primary, and Irshad, Sheeba, primary

Published
2023
Full Text
View/download PDF

45. Table S4 from 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer

Author

Peck, Barrie, primary, Bland, Philip, primary, Mavrommati, Ioanna, primary, Muirhead, Gareth, primary, Cottom, Hannah, primary, Wai, Patty T., primary, Maguire, Sarah L., primary, Barker, Holly E., primary, Morrison, Eamonn, primary, Kriplani, Divya, primary, Yu, Lu, primary, Gibson, Amy, primary, Falgari, Giulia, primary, Brennan, Keith, primary, Farnie, Gillian, primary, Buus, Richard, primary, Marlow, Rebecca, primary, Novo, Daniela, primary, Knight, Eleanor, primary, Guppy, Naomi, primary, Kolarevic, Daniela, primary, Susnjar, Snezana, primary, Milijic, Natasa Medic, primary, Naidoo, Kalnisha, primary, Gazinska, Patrycja, primary, Roxanis, Ioannis, primary, Pancholi, Sunil, primary, Martin, Lesley-Ann, primary, Holgersen, Erle M., primary, Cheang, Maggie C.U., primary, Noor, Farzana, primary, Postel-Vinay, Sophie, primary, Quinn, Gerard, primary, McDade, Simon, primary, Krasny, Lukas, primary, Huang, Paul, primary, Daley, Frances, primary, Wallberg, Fredrik, primary, Choudhary, Jyoti S., primary, Haider, Syed, primary, Tutt, Andrew N., primary, and Natrajan, Rachael, primary

Published
2023
Full Text
View/download PDF

46. Data from 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer

Author

Peck, Barrie, primary, Bland, Philip, primary, Mavrommati, Ioanna, primary, Muirhead, Gareth, primary, Cottom, Hannah, primary, Wai, Patty T., primary, Maguire, Sarah L., primary, Barker, Holly E., primary, Morrison, Eamonn, primary, Kriplani, Divya, primary, Yu, Lu, primary, Gibson, Amy, primary, Falgari, Giulia, primary, Brennan, Keith, primary, Farnie, Gillian, primary, Buus, Richard, primary, Marlow, Rebecca, primary, Novo, Daniela, primary, Knight, Eleanor, primary, Guppy, Naomi, primary, Kolarevic, Daniela, primary, Susnjar, Snezana, primary, Milijic, Natasa Medic, primary, Naidoo, Kalnisha, primary, Gazinska, Patrycja, primary, Roxanis, Ioannis, primary, Pancholi, Sunil, primary, Martin, Lesley-Ann, primary, Holgersen, Erle M., primary, Cheang, Maggie C.U., primary, Noor, Farzana, primary, Postel-Vinay, Sophie, primary, Quinn, Gerard, primary, McDade, Simon, primary, Krasny, Lukas, primary, Huang, Paul, primary, Daley, Frances, primary, Wallberg, Fredrik, primary, Choudhary, Jyoti S., primary, Haider, Syed, primary, Tutt, Andrew N., primary, and Natrajan, Rachael, primary

Published
2023
Full Text
View/download PDF

47. Supplementary Methods from 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer

Author

Peck, Barrie, primary, Bland, Philip, primary, Mavrommati, Ioanna, primary, Muirhead, Gareth, primary, Cottom, Hannah, primary, Wai, Patty T., primary, Maguire, Sarah L., primary, Barker, Holly E., primary, Morrison, Eamonn, primary, Kriplani, Divya, primary, Yu, Lu, primary, Gibson, Amy, primary, Falgari, Giulia, primary, Brennan, Keith, primary, Farnie, Gillian, primary, Buus, Richard, primary, Marlow, Rebecca, primary, Novo, Daniela, primary, Knight, Eleanor, primary, Guppy, Naomi, primary, Kolarevic, Daniela, primary, Susnjar, Snezana, primary, Milijic, Natasa Medic, primary, Naidoo, Kalnisha, primary, Gazinska, Patrycja, primary, Roxanis, Ioannis, primary, Pancholi, Sunil, primary, Martin, Lesley-Ann, primary, Holgersen, Erle M., primary, Cheang, Maggie C.U., primary, Noor, Farzana, primary, Postel-Vinay, Sophie, primary, Quinn, Gerard, primary, McDade, Simon, primary, Krasny, Lukas, primary, Huang, Paul, primary, Daley, Frances, primary, Wallberg, Fredrik, primary, Choudhary, Jyoti S., primary, Haider, Syed, primary, Tutt, Andrew N., primary, and Natrajan, Rachael, primary

Published
2023
Full Text
View/download PDF

48. Figure S1- S8 from 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer

Author

Peck, Barrie, primary, Bland, Philip, primary, Mavrommati, Ioanna, primary, Muirhead, Gareth, primary, Cottom, Hannah, primary, Wai, Patty T., primary, Maguire, Sarah L., primary, Barker, Holly E., primary, Morrison, Eamonn, primary, Kriplani, Divya, primary, Yu, Lu, primary, Gibson, Amy, primary, Falgari, Giulia, primary, Brennan, Keith, primary, Farnie, Gillian, primary, Buus, Richard, primary, Marlow, Rebecca, primary, Novo, Daniela, primary, Knight, Eleanor, primary, Guppy, Naomi, primary, Kolarevic, Daniela, primary, Susnjar, Snezana, primary, Milijic, Natasa Medic, primary, Naidoo, Kalnisha, primary, Gazinska, Patrycja, primary, Roxanis, Ioannis, primary, Pancholi, Sunil, primary, Martin, Lesley-Ann, primary, Holgersen, Erle M., primary, Cheang, Maggie C.U., primary, Noor, Farzana, primary, Postel-Vinay, Sophie, primary, Quinn, Gerard, primary, McDade, Simon, primary, Krasny, Lukas, primary, Huang, Paul, primary, Daley, Frances, primary, Wallberg, Fredrik, primary, Choudhary, Jyoti S., primary, Haider, Syed, primary, Tutt, Andrew N., primary, and Natrajan, Rachael, primary

Published
2023
Full Text
View/download PDF

49. Abstract PD9-06: Histopathological and molecular immune landscape and DNA damage response signatures to predict response to carboplatin and docetaxel in TNT trial TNBC cohort

Author

Tovey, Holly, primary, Sipos, Orsolya, additional, Hoadley, Katherine A, additional, Parker, Joel S, additional, Quist, Jelmar, additional, Kernaghan, Sarah, additional, Kilburn, Lucy, additional, Salgado, Roberto, additional, Loi, Sherene, additional, Kennedy, Richard D, additional, Roxanis, Ioannis, additional, Gazinska, Patrycja, additional, Pinder, Sarah E., additional, Bliss, Judith, additional, Perou, Charles M., additional, Haider, Syed, additional, Tutt, Andrew, additional, Grigoriadis, Anita, additional, and Cheang, Maggie Chon U, additional

Published
2023
Full Text
View/download PDF

50. Abstract P6-10-05: Mutations in the RNA Splicing Factor SF3B1 drive endocrine therapy resistance and confer a targetable replication stress response defect through PARP inhibition

Author

Bland, Phil, primary, Saville, Harry, additional, Read, Abigail, additional, Wai, Patty, additional, Muirhead, Gareth, additional, Curnow, Lucinda, additional, Nieminuszczy, Jadwiga, additional, Ravindran, Nivedita, additional, John, Marie, additional, Hedayat, Somaieh, additional, Barker, Holly, additional, Wright, James, additional, Yu, Lu, additional, Mavrommati, Ioanna, additional, Peck, Barrie, additional, Allen, Mark, additional, Gazinska, Patrycja, additional, Pemberton, Helen, additional, Gulati, Aditi, additional, Nash, Sarah, additional, Noor, Farzana, additional, Guppy, Naomi, additional, Roxanis, Ioannis, additional, Barlow, Samantha, additional, Kalirai, Helen, additional, Coupland, Sarah, additional, Broderick, Ronan, additional, Alsafadi, Samar, additional, Houy, Alexandre, additional, Stern, Marc-Henri, additional, Pettit, Stephen, additional, Choudhary, Jyoti, additional, Haider, Syed, additional, Niedzwiedz, Wojciech, additional, Lord, Christopher, additional, and Natrajan, Rachael, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results